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Background: Large anatomical variations occur during the course of intensity-modulated radiation therapy (IMRT)
for locally advanced head and neck cancer (LAHNC). The risks are therefore a parotid glands (PG) overdose and a
xerostomia increase.
The purposes of the study were to estimate:
- the PG overdose and the xerostomia risk increase during a “standard” IMRT (IMRTstd);
- the benefits of an adaptive IMRT (ART) with weekly replanning to spare the PGs and limit the risk of xerostomia.
Material and methods: Fifteen patients received radical IMRT (70 Gy) for LAHNC. Weekly CTs were used to
estimate the dose distributions delivered during the treatment, corresponding either to the initial planning (IMRTstd)
or to weekly replanning (ART). PGs dose were recalculated at the fraction, from the weekly CTs. PG cumulated
doses were then estimated using deformable image registration. The following PG doses were compared:
pre-treatment planned dose, per-treatment IMRTstd and ART. The corresponding estimated risks of xerostomia
were also compared. Correlations between anatomical markers and dose differences were searched.
Results: Compared to the initial planning, a PG overdose was observed during IMRTstd for 59% of the PGs, with
an average increase of 3.7 Gy (10.0 Gy maximum) for the mean dose, and of 8.2% (23.9% maximum) for the
risk of xerostomia. Compared to the initial planning, weekly replanning reduced the PG mean dose for all the
patients (p < 0.05). In the overirradiated PG group, weekly replanning reduced the mean dose by 5.1 Gy (12.2 Gy
maximum) and the absolute risk of xerostomia by 11% (p < 0.01) (30% maximum). The PG overdose and the
dosimetric benefit of replanning increased with the tumor shrinkage and the neck thickness reduction (p < 0.001).
Conclusion: During the course of LAHNC IMRT, around 60% of the PGs are overdosed of 4 Gy. Weekly replanning
decreased the PG mean dose by 5 Gy, and therefore by 11% the xerostomia risk.
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The treatment of unresectable Head & Neck Cancer
(HNC) consists of a chemoradiotherapy [1,2]. One of
the most common toxicity of this treatment is xerosto-
mia, inducing difficulties in swallowing and speaking,
loss of taste, and dental caries, with therefore a direct
impact on patient quality of life. Xerostomia is mainly
caused by radiation induced damage mainly to the par-
otid glands (PG), and to a lesser extend to the subman-
dibular glands [3]. Intensity modulated radiotherapy
(IMRT) permits to deliver highly conformal dose in
complex anatomical structures, while sparing critical
structures. Indeed, three randomized studies have dem-
onstrated improving (PG) sparing by using IMRT com-
pared to non-IMRT techniques, resulting in better
salivary flow and decreased xerostomia risk [4-6]. How-
ever, large variations can be observed during the course
of IMRT treatment, such as body weight loss [7,8], pri-
mary tumor shrinking [7], and PG volume reduction [9].
Due to these anatomical variations and to the tight
IMRT dose gradient, the actual administered dose may
therefore not correspond to the planned dose, with a
risk of radiation overdose to the PGs (Figure 1) [10,11].
This dose difference clearly reduces the expected clinical
benefits of IMRT, increasing the risk of xerostomia. Al-
though bone-based image-guided radiation therapy
(IGRT) allows for setup error correction, the actual de-
livered dose to the PGs remains higher than the planned
dose [12], due to the fact that IGRT does not take
shape/volume variations into account. By performing
one or more new planning during the radiotherapy treat-
ment, adaptive radiotherapy (ART) aims to correct such
uncertainties. ART has been already shown to decrease
the mean PG dose during locally advanced head and
neck cancer IMRT [13], but no surrogate of the PG doseFigure 1 Illustration of the anatomical variations on the dose distribu
showing the PG overdose without replanning (B) and the benefit of replan
delivered dose without replanning during the treatment (Week 3). C: Adap
the same fraction (Week 3). PGs are shown by the red line. The full red rep
thickness. Figure 1B and 1C compared to 1A shows that the PGs and the CTV
variations have led to dose hotspots in the neck, close to the internal part of
even better than on the planning (Figure 1A).difference and of the dosimetric benefit of ART has yet
been identified. In the context of IMRT for locally ad-
vanced HNC, this study sought to:
– estimate the difference between the planned dose
and the actual delivered dose (without replanning)
to the PGs, i.e., the PG overdose;
– estimate the PG dose difference with replanning and
without replanning to spare the PGs while keeping
the same planning target volume (PTV), i.e., the
benefit of ART;
– identify anatomical markers correlated with these
dose differences (PG overdose and ART benefit).
Materials and methods
Patients and tumors
The study enrolled a total of 15 patients with a mean age
of 65 years (ranging from 50 to 87 years). Patient, tumor,
and treatment characteristics are provided on Table 1. All
tumors were locally advanced (Stage III or IV, AJCC 7th
ed). The mean PG volume was 25.3 cc (ranging from
16.6 cc to 52.1 cc, standard deviation (SD): 8.1 cc).
Treatment and planning
All patients underwent IMRT using a total dose of 70 Gy
(2 Gy/fraction/day, 35 fractions), with a simultaneous inte-
grated boost technique [14] and concomitant chemother-
apy. Planning CTs (CT0) with intravenous contrast agents
were acquired with 2 mm slice thickness from the vertex
to the carina. A thermoplastic head and shoulder mask
with five fixation points was used. PET-CT and MRI co-
registration was used for tumor delineation. Three target
volumes were generated. Gross tumor volume (GTV) cor-
responded to the primary tumor along with involved
lymph nodes. Clinical target volume 70 Gy (CTV70) wastion. IMRT dose distributions at different times for a given patient,
ning (C). A: Planned dose on the pre-treatment CT (CT0). B: Actual
tive planned dose with replanning to spare the parotid glands (PG) at
resents the Clinical Target Volume (CTV70). The arrow show the head
70 volumes and the neck thickness have decreased. These anatomical
the two PG (Figure 1B). Replanning (Figure 1C) allowed to spare the PG
Table 1 Patient, tumor, and treatment characteristics at the initial planning (CT0)
ID Gender Age Tumor
localization
TNM Volume (cc) Dmean (Gy) Xerostomia
NTCP (%) [21]CTV70 HLP CLP HLP CLP
HLP CLP
1 M 86 Tonsil T3N1 45.2 52.1 48.6 30.2 31.1 26.5 28.3
2 F 63 Tonsil T2Nx 26.3 31.1 27.5 31.4 26 29.0 18.7
3 M 74 Oropharynx T3N2c 181.5 24.9 20.7 37.9 31.1 44.3 28.4
4 F 66 Oropharynx T2N2c 107.2 27.8 23.4 32.9 27.9 32.3 22.0
5 M 57 Velum T3N0 62.4 20.7 18.0 28.1 27.8 22.4 21.7
6 M 67 Oropharynx T3N2c 156.2 24.5 22.7 30.8 29.4 24.7 21.4
7 M 52 Oropharynx T4N2 165.1 N/A 21.6 N/A 28.7 N/A 23.4
8 M 67 Trigone T4N1 139.3 22.0 19.3 30.7 29.2 27.4 24.4
9 F 65 Oropharynx T3N3 237.5 23.9 20.2 42.4 31.1 55.2 28.2
10 F 65 Oropharynx T4N3 257.9 N/A 24.5 N/A 35.2 N/A 37.7
11 M 50 Oropharynx T4N2c 434.5 N/A 17.7 N/A 36.3 N/A 40.3
12 M 53 Oropharynx T3N0 14.4 16.6 23.3 41.3 24.2 52.9 15.9
13 M 73 Oropharynx T3N2c 147.0 29.4 29.2 54.6 32.2 81.7 30.7
14 M 56 Larynx T3N0 14.0 22.8 29.2 19.7 9.2 10.1 2.7
15 M 75 Hypopharynx T2N2 76.3 20.3 22.4 29.4 29.1 25.0 24.4
M: male; F: female; CT0: initial planning; CTV70: clinical target volume receiving 70 Gy; PGs: parotid glands; HLP: homolateral PGs; CLP: contralateral PGs; Dmean: mean
dose at initial planning; N/A: not applicable (PGs included in the CTV), NTCP: normal tissue complication risk of xerostomia defined as a salivary flow ratio <25% of the
pretreatment one [21].
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justed to exclude air cavities and bone mass without evi-
dence of tumor invasion. CTV63 corresponded to the area
at high-risk of microscopic spread, while CTV56 corre-
sponded to the prophylactic irradiation area. GTV, CTV63,
CTV56, and all organs at risk were manually delineated on
each CT slice. Adding a 5 mm 3D margin around the
CTVs generated the PTVs. PTV expansion was limited to
3 mm from the skin surface in order to avoid the build-up
region and to limit skin toxicity [15]. All IMRT plans were
generated using Pinnacle V9.2. Seven Coplanar 6-MV
photon beams were employed with a step and shoot IMRT
technique. The prescribed dose was 70 Gy to PTV70,
63 Gy to PTV63, and 56 Gy to PTV56. The collapsed cone
convolution/superposition algorithm was used for dose
calculation. The maximum dose within the PTV was
110% (D2%). The minimum PTV volume covered by the
95% isodose line was 95%. Dose constraints were set ac-
cording to the GORTEC recommendations [16]: a mean
dose (Dmean) <30 Gy and a median dose <26 Gy for
contralateral PGs.
Patients were treated as planned on CT0 and no
changes were applied to dose distribution during treat-
ment. During the treatment course, weekly in-room
stereoscopic imaging corrected set-up errors >5 mm. All
patients signed an informed consent form. The study
was approved by the institutional review board (ARTIX
study NCT01874587).Weekly dose estimations, in cases of replanning and
without replanning
During the treatment, each patient underwent six weekly
CTs (CT1 to CT6) according to the same modalities as
CT0, except for the intravenous contrast agents (not sys-
tematically used, particularly in case of cisplatin based
chemotherapy). For each patient, the anatomical structures
were manually segmented on each weekly CT by the same
radiation oncologist. In case of complete response, initial
macroscopically-involved areas were still included in the
CTV70, which was adjusted to exclude any air cavities and
bone mass without evidence of initial tumor invasion.
Actual weekly doses (Figure 2, Step 1A) were esti-
mated by calculating the dose distribution on the weekly
CT, using treatment parameters and isocenter from
CT0. Weekly re-planned doses (Figure 2, Step 1C) were
calculated by generating a new IMRT plan on each
weekly CT in accordance with the dose constraints de-
scribed for the initial planning. PTV coverage did not
differ between initial planning and weekly re-planned
CT. The dose constraints for the organs at risk have
respected the GORTEC recommendations at the initial
planning and in all replanning.
Total cumulated dose estimations by deformable registration
Cumulated doses were estimated for the two scenarios,
with or without replanning (Figure 2 Steps 1B and 1D),
according to the following deformable image registration
Figure 2 Overall study flow chart. Weekly CT scans were performed during the 7 weeks of treatment. Doses were calculated on each weekly
fraction, corresponding either to the initial planning (step 1A) or to a replanning to spare the parotid glands (step 1C). Corresponding cumulated
doses were calculated (steps 1B and 1C) using elastic registration. Doses were then compared.
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rithm) [17]. For PGs on each CT, a signed distance map
was generated to represent the squared Euclidean dis-
tance between each voxel and the PG surface. Distance
maps of each PG were then registered using the Demons
registration algorithm [18]. The resulting deformation
fields were employed to map the weekly dose distribu-
tions to the planning CT using tri-linear interpolation.
Next, the mapped dose distributions were summed to
estimate the cumulated dose for each PG. The average
Dice score for PG registration, from the weekly CT to
each planning CT was computed as followed:
Dice score = 2×(|A∩B|)/(|A| + |B|), where: A is the de-
lineated PG contour on the weekly CT, B is the planning
contour propagated by the registration and |.| denotes
the number of voxels encompassed by the contour. The
Dice score ranges from 0 (worst case: no match between
both contours) to 1 (perfect match) [19]. A 3D dose dif-
ference in the PG was calculated between the cumulated
dose distribution and planned dose distribution.
Anatomical variation description
Anatomical variations (between CT0 and weekly CTs)
were characterized by variations in CTV70 and PG vol-
umes, in the distances between PGs and CTV70 and in
the thickness of the neck (at the level of the geometrical
centers of the PGs). The distance between PGs and
CTV70 corresponded to the minimal distance between
the surfaces of the two contours (PG-CTVds), computed
using an Euclidean distance map of the first contour, it-
eratively considering all the points of the second contour
and keeping the resulting minimal distance.Statistical analysis
The impact of the anatomical variations on PG dose was
analyzed considering Dmean and the full DVH. Their im-
pact on the risk of xerostomia was estimated by using
the LKB NTCP model (n = 1, m = 0.4, and TD50 = 39.9)
[20,21], the complication being defined as a salivary flow
ratio <25% of the pretreatment one [22].
The mean PG dose differences between the weekly doses
(with and without replanning) and the planned dose were
calculated (Figure 2). The PG overdose was assessed as the
difference between the dose without replanning (at the frac-
tion or cumulated) and the dose at the planning. The be-
nefit of weekly replanning was assessed as the difference
between the doses with replanning and without replanning
(at the fraction or cumulated). Linear mixed-effects models
were used to test if the following parameters were correlated
with the PG overdose or the benefit of the weekly replan-
ning: initial volumes of the CTV70 and of the PGs, decreas-
ing (between the weekly CT and the planning CT) of the
volume of the CTV70 (in cc and %) and the PGs (in cc and
%), shortening of the distance between PGs and CTV70, re-
duction of the head thickness and the time between the
CT0 and the beginning of treatment. All dose and volume
comparisons were performed using nonparametric tests
(Wilcoxon test). Statistical analysis was carried out using the
Statistical Package for the Social Sciences V 20.0.
Results
Since 3 ipsilateral PGs were completely included within
the PTV (Patient number 7, 10 and 11), they were ex-
cluded from the analysis, resulting in a total of 27 PGs an-
alyzed. The average Dice score [19] for PG registration,
Castelli et al. Radiation Oncology  (2015) 10:6 Page 5 of 10from the weekly CT to each planning CT was 0.92 (from
0.83 to 0.95).
Quantification of anatomical variations during the
7 weeks of treatment
From CT0 to CT6, the PG volumes decreased by a mean
value of 28.3% (ranging from 0.0 to 63.4%, SD 18%), corre-
sponding to an average decrease of 1.1 cc/week (ranging
from 0.0 to 2.2 cc/week). The CTV70 decreased by a mean
value of 31% (ranging from 73% to −13%, SD 28%).
The distance between the PGs and the CTV (PG-CTVds)
decreased in 74% of the PGs by 4.3 mm on average (ran-
ging from 0.1 to 12 mm, SD 3.7 mm), whereas it increased
in the other 26% of the PGs by 3.2 mm on average (ranging
from 1.1 to 6.3 mm, SD 2.1 mm).
The thickness of the neck decreased for 78% of the pa-
tients by a mean value of 7.9 mm (ranging from 0.1 to
26.6 mm, SD 6.2 mm).
Dose comparison between planned dose, and doses with
or without replanning in PGs
The per-treatment PG doses (with or without replanning)
were analyzed, first considering the weekly fractions and
then, using the cumulated doses from all weekly fractions,
for all the 15 patients. The results are shown in Table 2.
PG dose comparisons at the per-treatment weekly fraction
In order to assess the PG overdose, comparison was first
made between the dose at the fraction without replanning
(Figure 2 Step 1A) and the planned dose. For 67% of the
plans, the Dmean increased on average by 4.8 Gy (up to
24.9 Gy, SD 4.6 Gy). In the other 33% of plans, the Dmean
decreased by 3.9 Gy (up to 10.7 Gy, SD 2.9 Gy). The vari-
ation of the mean PG dose during the treatment was
showed Figure 3 for two representative patients.
Then, to assess the benefit of replanning, comparison
was made between the dose with (Figure 2 step 1C) andTable 2 Parotid gland overdose and replanning benefit asses
all the 15 patients
Dmean (Gy),mean (Min-max;SD
Planned dose (1)
Doses at the fraction Without replanning (2)
With replanning (3)
PG overdose (4) = (2)-(1)
Replanning benefit (5) = (3)-(2)
Cumulated doses Without replanning (2)
With replanning (3)
PG Overdose (4) = (2)-(1)
Replanning benefit (5) = (3)-(2)
PGs: parotid glands; Dmean: First, the mean PG dose was calculated for each patien
calculated for each patient (DMeanPt). Finally, the mean of the DmeanPt was calcul
p values are calculated using the Wilcoxon test, to test if the Dmean in (1) and (2),without replanning (Figure 2 Step 1A). In 85% of the
plans, replanning decreased the Dmean on average by
4.6 Gy (up to 23.8 Gy, SD 4.0 Gy).
PG dose comparisons using the cumulated doses and the
corresponding estimated xerostomia risks
A PG overdose was reported in 59% (N = 16) of the
PGs. Figure 4a shows the Dmean difference for each PG
of each patients. Ten out of fifteen patients received a
higher Dmean in at least one PG (6 patients in the 2
PGs), which corresponded to a Dmean increase of an
average of 3.7 Gy (ranging from 0.4 to 10.0 Gy, SD
2.9 Gy). Figure 5 shows the average planned DVH (red
line) and the average cumulated DVH without replan-
ning (blue line).
Figure 4b shows the corresponding difference in the
estimated xerostomia risk. The average absolute in-
creased risk of xerostomia was 3% (ranging from −16.7
to 23.9%, SD 2.9%) in all patients, and was 8.2% (ranging
from 3.8 to 23.9%, SD 7.1%) among patients with an in-
creased dose to PGs.
Weekly replanning enabled the Dmean to be reduced to
at least the same value as that of the pre-treatment plan-
ning for all over-irradiated PGs (Figure 6). In the sub-
group of over-irradiated PGs, the mean Dmean difference
between the cumulated doses with replanning and with-
out replanning was therefore 5.1 Gy (ranging from 0.6 to
12.2 Gy, SD 3.3 Gy) (p = 0.001). In the subgroup of non-
over-irradiated PGs, this mean Dmean difference was
1.4 Gy (ranging from 0 to 4.1 Gy, SD 1.7 Gy) (p = 0.001).
Figure 5 displays the impact of the replanning to de-
crease the PG dose, with the average cumulated DVH
with replanning (green line) and without replanning
(blue line).
In the over-irradiated PG group, the replanning de-
creased the xerostomia risk by 11% on average (ranging
from 1 to 30%, SD 8%) (p < 0.01).sments, based on the fraction or the cumulated doses, for
) p-value
30.9 (9.2-54.6; 7.9) -
33.0 (7.7-61.2; 9.9)
29.4 (4.1-51.7; 8.3)
1.8 (−10.6-24.9; 5.8) <0,001
3.8 (0–23.8; 4.0) <0,001
32.0 (8.7-57.6; 9.3) -
28.6 (4.6-51.2; 8.4)
1.1 (−7.9-10.0; 4.1) 0,1
3.6 (0–12.2; 3.3) <0,001
t and each week (DmeanWeekly). Then, the mean of the DMeanWeekly was
ated for the whole population (D(mean)).
and if the Dmean in (2) and (3) are statistically different.
Figure 3 Variation over time of the mean PG dose for two representative patients. Red line corresponding to patient N°1 who presenting an
increasing of the mean PG dose cumulated. Blue line corresponding to the patient N°12 who presenting a decreasing of the mean PG dose cumulated.
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replanning benefit
PG overdose and replanning benefit (at the fraction or cu-
mulated) increased with the CTV70 shrinkage and the reduc-
tion of neck thickness (p < 0.01). At the fraction, a reduction
of 10 cc of the CTV70 or of 1 mm of the neck thicknessFigure 4 Parotid gland overdose assessment: Difference between the
at the planning, in each of the parotid gland, for each of the 15 patie
presented Figure 4b. NTCP: normal tissue complication risk of xerostomia dleads to an increase of the mean PG dose of 0.3 Gy. The
PG volume variation has no impact on the mean PG dose.
Discussion and conclusion
The main goal of definitive chemoradiotherapy in locally
advanced HNC is to improve locoregional control, whilemean cumulated dose (without replanning) and the mean dose
nts (4a). The corresponding impact on the xerostomia risk (%) is
efined as a salivary flow ratio <25% of the pretreatment one [21].
Figure 5 Mean parotid gland dose-volume histograms (DVHs) showing the impact of replanning on the over-irradiated PGs (n = 16).
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during the whole course of IMRT and therefore xerosto-
mia is a major challenge. Indeed, we found the majority of
the PGs (59%) being overirradiated of a mean dose of 4 Gy
(up to 10 Gy), resulting to an absolute increase risk of
xerostomia of 8% (up to 24%). The ART strategy appears
to benefit not only to the over-irradiated PG patients,
reducing the mean dose of 5 Gy (up to 12 Gy) and theFigure 6 Replanning benefit assessement: cumulated mean dose diffe
replanning, in each of the parotid gland (ipsilateral and contralateral
xerostomia risk (%) (6b). NTCP: normal tissue complication risk of xerostoxerostomia risk of 11% (up to 30%), but also to the non-
over-irradiated PGs. These results suggest thus a large use
of ART for the majority of locally advanced HNC patients.
In our study, four patients (N° 4, 7, 10 and 12) have not
clear benefit from replanning. These patients were pre-
sented a spontaneous decrease of the mean PG dose dur-
ing the treatment. No more gain was possible with the
replanning due to the other constraints (homogeneity,rence between the dose with replanning and the dose without
), for each of the 15 patients (6a), and corresponding estimated
mia defined as a salivary flow ratio <25% of the pretreatment one [21].
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constraints has been respected for all the replanning.
The dosimetric benefit of ART has been shown in a
limited number of studies, and not exclusively for the
PGs. In a series of 22 patients, Schwartz et al. evaluated
the impact of one and two replanning using daily CT on
rails [23]. The mean PG dose was decreased of 3.8% for
contralateral PGs and of 9% for ipsilateral PGs, with pos-
sible sparing of the oral cavity and larynx. In another
series of 20 patients, a single replanning performed at
the 3rd or 4th week of treatment decreased the mean
PG dose of 10 Gy [9]. On the other hand, Castadot et al.
didn’t show any dosimetric benefits for PGs when using
four replanning in a series of 10 patients, however redu-
cing the spinal cord dose and improving the CTV56 dose
conformation [24].
The optimal number and time of replanning are unclear.
Wu et al. concluded that one replanning decreased the
mean PG dose by 3%, two replanning by 5%, and six re-
planning by 6% [13]. A “maximalist” weekly replanning
strategy was considered feasible in our study, as in an on-
going randomized study (ARTIX) comparing one IMRT
based planning to a weekly based IMRT replanning. The
benefit of such strategy has to be demonstrated compared
to other replanning strategies. Ongoing study (like ART-
FORCE trial) test the benefit of only one replanning [24].
The benefit of each supplementary weekly replanning has
to be evaluated. A true adaptive RT strategy should be
personalized to each patient, ranging potentially from no
re-planning to a maximalist weekly replanning. Ideally, re-
planning decisions may likely be based on either geomet-
rical criteria or cumulated dose monitoring corresponding
to the dose-guided RT approach. Replanning is also par-
ticularly time-consuming, complete delineation taking up
to 2.5 hours in our experience and that of others [25-28].
Deformable image co-registration software can be used to
propagate the OAR contours from the initial planning CT
to the per-therapeutic planning CT, reducing the delinea-
tion time by approximately a factor 3 [26,28]. The CTV
delineation should be however carefully checked, to pre-
vent recurrence due to inadequately reduced CTV. In-
deed, the goal of ART in our study was to spare the PGs
during treatment as they were spared at the planning,
while keeping the same appropriate CTV coverage (and
not to reduce the CTV coverage).
The analysis of the anatomical variations occurring
within the course of IMRT is crucial to understand the
overdose of the PGs and to identify early the sub-group
of the overdosed PGs (59%). We found that mean vol-
umes decreased by 28% for the PGs and 31% for the
CTV, in agreement with the literature reporting values
of 15% to 28% for the PGs, 69% for the GTV, and 8% to
51% for the CTV [7,9,13,23,26,29]. We found that the
PGs overdose (without replanning) and the dosimetricbenefit of replanning increased with the tumor shrinkage
and the reduction of head thickness. The last one is likely
explained by loss of weight, tumor shrinking and decrease
of the PG volume. The reduction of the head thickness
leads consequently to the occurrence of dose hotspot in
the neck, close or within the PGs (Figure 1). Other studies
also found that reduction of the neck diameter increases
the risk of over-irradiation [30,31]. The variation of the
mean PG dose was more important between the CT0 and
the CT1 than between each weekly CT. This difference
may be explained by the delay between CT0 and the first
weekly CT. In our study, the PG dose differences between
the fraction and the initial planning are likely related to
both the set-up error (we did not quantified) and the ana-
tomical structures volume/shape variations. Systematic
set-up errors may increase the mean PG dose by around
3% by mm of displacement [32]. This point suggests, for a
daily practice, to combine both a daily bone registration to
correct the set-up errors and replanning to correct the
anatomical variations.
Fraction comparison only provides information for a
specific moment and there is a need for full treatment
dose evaluation and comparison. Deformable registra-
tion enables dose fraction accumulation [33]. Since PG
shape and volume variations were limited, our study’s
Dice scores were relatively high (0.92). However, the
Dice score does not provide any information regarding
the registration’s anatomical “point to point” corres-
pondence accuracy. Moreover, the possibility of PG de-
fects observed over the course of radiotherapy [34]
should prompt careful consideration of this cumulated
dose approach, thereby justifying an independent “frac-
tion to fraction” dose analysis. Our results, based on
both weekly fraction and cumulated dose, were consist-
ent. The 3D dose visualization and differential DVH of
the dose difference between the cumulated dose and
planning dose (Figure 1) revealed moreover the hetero-
geneity of hotspot distribution in PGs, which may also
impact on the xerostomia risk. The cranial part of the
PGs seems to be more critical [35,36], maybe due to the
presence of an important concentration of salivary gland
stem cells at this level [37]. The possible heterogeneity
of the radiosensitivity within the PG could be therefore
more carefully investigated in order to consider to spare
not only the full gland (represented by a mean dose end-
point) but also subparts of the gland. Indeed, relatively
small dose (10 Gy) within the PG may cause severe loss
of function [38], and dose greater than 20 Gy may cause
up to 90% loss of the acinar cells [39]. It seems also that
radiation-induced gland dysfunction are due to mem-
brane damage, causing secondarily necrosis of acinar
cells and atrophy of the lobules [40].
Our study exhibits limitations. The small patient num-
ber did not allow us to analyze the potential impact of
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were always delineated by the same radiation oncologist,
intra-observer variabilities in organ delineation are also
potentially responsible for uncertainties. Moreover, the
clinical benefit of the weekly replanning has been esti-
mated and was not reported in the study.
In conclusion, an ART strategy combining a daily bone
registration and a weekly replanning may be proposed
for locally advanced HNC, with an expected benefit to
decrease xerostomia. This PG-sparing strategy appears
however particularly complex and should be therefore
assessed within prospective trials, with a special atten-
tion for CTV delineation. The optimal number and time
of replanning are unclear. The benefit of a weekly re-
planning strategy versus other replanning strategies have
to been demonstrated.
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